• US: +1 9176726599
  • Login

Imaging Agents Market Status (2018-2022) and Forecast Market Analysis, Regional Outlook, Segment Growth Potential, and Competitive Market Share Analysis, 2023-2030

Format: PDF | Pages: 332 | Report ID: MRS1260


Report Description

The global Imaging Agents market size was valued at USD 8,907.6 million in 2022, expanding at a CAGR of 5.8% from 2023-2030 to reach 14,008.9 Million USD in 2030.

Market Dynamics

The imaging Agents market is expected to witness substantial growth over the forecast period. Over the course of the analysis period, it is anticipated that the rising incidences of cancer and CVD cases will fuel market demand for imaging agents. For instance, the WHO (World Health Organization) reports that over 9.6 million people died from cancer in 2018, making it the second largest cause of death globally. The American Heart Association estimates that globally, 18.6 million people died from cardiovascular disease in 2019. The burden of cardiovascular and cancer disorders worldwide has increased as a result of rising alcohol and cigarette use. Nearly 22% of all cancer deaths are related to tobacco use. As a result, these factors will increase the demand for imaging procedures and imaging agents, which will be advantageous for the overall market sales of imaging agents.

Imaging tools are used to assess cancer's stages (how far along it is), as well as whether it has spread to blood vessels or essential organs. The majority of cardiac MRI procedures also employ intravenous gadolinium-based contrast agents (GBAs) to improve the visibility of the heart muscle and blood flow. Gadolinium, microbubble, and iodine imaging agents are also needed for a rise in cancer imaging procedures for the thyroid, lung, and breast. As a result, the market revenue for imaging agents will increase due to the rising popularity of using imaging agents to pre-diagnose breast cancer and colorectal cancer.

Regional Insights

The Asia Pacific is estimated to witness the fastest growth in the global market. During the projected period, Asia Pacific is anticipated to develop at the fastest rate due to the region's growing geriatric population and rising demand for cutting-edge imaging technologies. Additionally, it is projected that during the forecasted period, the advanced medical imaging business will rise in tandem with the expanding medical tourism sector in Asian nations. Due to the rapidly growing demand for healthcare services, the availability of skilled healthcare workers, and the availability of advanced healthcare facilities and services at lower costs than in developed nations in North America and Europe, countries like India, China, and Japan are creating growth opportunities.

Segment Dynamics

The Imaging Agents market is fragmented into the type, applications, and modality segments. Based on type, the iodinated Contrast Media segment is anticipated to dominate the market. By application, the oncology segment of the market is projected to grow at the highest rate (CAGR) during the forecast period. By modality, the X-ray segment is expected to hold the majority of the market share.

Competitive Insights

 

The Imaging Agents market is highly competitive in nature with the presence of local & international players. Major players in the industry engage in strategic mergers & acquisitions, partnerships, and new product launches to remain competent in the market. For example, in May 2022, Lantheus received FDA approval for PYLARIFY. It is a PSMA PET imaging agent for prostate cancer that helps to visualize bone, soft tissue, and lymph node metastases.

The report begins with an overview of the Industry Chain structure, and describes the industry environment, then analyses market size and forecast of Imaging agents by type, region, and application. In addition, this report introduces the market competition situation among the vendors and company profile,, market price analysis, and value chain features are covered in this report.

Company Coverage (Company Profile, Sales Revenue, Price, Gross Margin, Main Products, etc.):

  • Eurofins Scientific Se (Luxembourg)
  • GE Healthcare
  • Eli Lily
  • Bayer Healthcare Pharmaceuticals
  • Alliance Medical
  • Bracco Diagnostics, Inc.
  • Aytu BioScience, Inc.
  • Curium
  • Guerbet Group
  • Lantheus Medical Imaging, Inc.
  • Trivitron Healthcare
  • Beijing Beilu Pharmaceutical

Type Coverage (Market Size & Forecast, Main Consumer Analysis, etc.):

  • lodinated Contrast Media
  • Gadolinium-based Contrast Media
  • Microbubble Contrast Media
  • Barium-based Contrast Media

Application Coverage (Market Size & Forecast, Main Consumer Analysis etc.):

  • Oncology
  • Cardiology
  • Gastrointestinal
  • Neurology
  • Others

Modality Coverage (Market Size & Forecast, Main Consumer Analysis etc.):

  • X-Ray
  • Computed Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
  • Ultrasound
  • Others

Region Coverage (Regional Consumption, Demand & Forecast by Countries etc.):

  • North America (U.S., and Canada)
  • Europe (Germany, U.K., France, Italy, Spain etc.)
  • Asia-Pacific (China, India, Japan, Indonesia, Malaysia, Australia, South Korea, etc.)
  • South America (Brazil, Mexico, Argentina etc.)
  • Middle East & Africa (Saudi Arabia, Kuwait, UAE, South Africa etc.)

Frequently Asked Questions

The global Imaging Agents market size was valued at USD 8,907.6 million in 2022, expanding at a CAGR 5.8% from 2023-2030 to reach 14,008.9 Million USD in 2030.
North America captured the highest revenue in 2021 and is projected to continue its dominance during the study period.
The global Imaging Agents market is expanding at a CAGR 5.8% from 2023-2030 to reach 14,008.9 Million USD in 2030.
Asia Pacific (especially China, and India) region is projected to grow at the fastest growth rate during the study period.
The Imaging Agents market is highly competitive in nature with the presence of local & international players. Major players in the industry engage in strategic merger & acquisition, partnership, and new product launches to remain competent in the market. For example, in May 2022, Lantheus received FDA approval for PYLARIFY. It is a PSMA PET imaging agent for prostate cancer that helps to visualize bone, soft tissue, and lymph node metastases.

Why Choose Market Research Strategy?

  Authenticated Data Sources

We utilize market analysis/information from verified authenticated data sources to scoop accurate research reports

  Express Delivery

We understand the urgency of our clients and their clients' in the competitive space thus, deliver the report in minimum turnaround

  Gain Instant Access

Without further ado, choose us and get instant access to reliable analysis to help you make the right business decisions.

  Our Pledge to You

We abide by the information security policy and adheres to keep your private and business information confidential and secure.

Copyright © 2022 Market Research Strategy, All rights reserved.